Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Sara M TolaneyMasakazu ToiPatrick NevenJoohyuk SohnEva-Maria GrischkeAntonio LlombartHatem H SolimanHong WangSameera WijayawardanaValerie M JansenLacey M LitchfieldGeorge W SledgePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Abemaciclib plus fulvestrant was effective regardless of PIK3CA or ESR1 mutation status, with benefit in both PFS and OS, with a numerically greater improvement in median PFS relative to placebo plus fulvestrant for PIK3CA- or ESR1-mutant tumors compared with the respective wild-type subgroups, in women with HR+, HER2- ABC that had progressed on ET.